 Jody Tanabe
Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 59 | 2025 | 3408 | 3.480 |
Why?
| | Substance-Related Disorders | 18 | 2019 | 1022 | 3.390 |
Why?
| | Brain | 37 | 2025 | 2679 | 2.600 |
Why?
| | Brain Mapping | 22 | 2024 | 574 | 1.930 |
Why?
| | Nerve Net | 8 | 2019 | 260 | 1.720 |
Why?
| | Cerebrovascular Circulation | 8 | 2022 | 226 | 1.710 |
Why?
| | Cerebral Cortex | 15 | 2019 | 437 | 1.630 |
Why?
| | Prefrontal Cortex | 6 | 2017 | 305 | 1.440 |
Why?
| | Decision Making | 9 | 2017 | 851 | 1.370 |
Why?
| | Image Processing, Computer-Assisted | 22 | 2019 | 744 | 1.350 |
Why?
| | Acetates | 2 | 2021 | 100 | 1.310 |
Why?
| | Impulsive Behavior | 7 | 2015 | 128 | 1.270 |
Why?
| | Neuroimaging | 7 | 2025 | 279 | 1.190 |
Why?
| | Frontal Lobe | 7 | 2015 | 154 | 1.180 |
Why?
| | Gambling | 5 | 2015 | 31 | 1.060 |
Why?
| | Thalamus | 4 | 2021 | 100 | 0.980 |
Why?
| | Nicotine | 6 | 2013 | 303 | 0.950 |
Why?
| | Limbic System | 4 | 2015 | 47 | 0.930 |
Why?
| | Alzheimer Disease | 5 | 2025 | 519 | 0.900 |
Why?
| | Frontotemporal Dementia | 1 | 2024 | 37 | 0.900 |
Why?
| | Behavior | 3 | 2021 | 92 | 0.860 |
Why?
| | Risk-Taking | 3 | 2015 | 347 | 0.850 |
Why?
| | Psychotic Disorders | 2 | 2024 | 151 | 0.820 |
Why?
| | Nicotinic Agonists | 5 | 2011 | 125 | 0.780 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2019 | 176 | 0.770 |
Why?
| | Learning | 2 | 2019 | 403 | 0.750 |
Why?
| | Sex Characteristics | 4 | 2020 | 737 | 0.740 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 73 | 0.730 |
Why?
| | Neostriatum | 2 | 2014 | 34 | 0.710 |
Why?
| | Pursuit, Smooth | 4 | 2005 | 19 | 0.710 |
Why?
| | Reward | 3 | 2023 | 240 | 0.700 |
Why?
| | Neuropsychiatry | 1 | 2020 | 17 | 0.700 |
Why?
| | Psychomotor Performance | 5 | 2017 | 313 | 0.680 |
Why?
| | Neural Pathways | 6 | 2017 | 302 | 0.670 |
Why?
| | Alcoholism | 4 | 2021 | 766 | 0.660 |
Why?
| | Software | 1 | 2024 | 608 | 0.650 |
Why?
| | Craving | 1 | 2019 | 40 | 0.620 |
Why?
| | Central Nervous System Depressants | 1 | 2019 | 82 | 0.620 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2019 | 57 | 0.620 |
Why?
| | Schizophrenia | 7 | 2023 | 431 | 0.600 |
Why?
| | Drug Users | 2 | 2016 | 41 | 0.590 |
Why?
| | Gray Matter | 2 | 2015 | 81 | 0.570 |
Why?
| | Male | 62 | 2025 | 63681 | 0.570 |
Why?
| | Adult | 45 | 2025 | 35576 | 0.560 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 28 | 0.550 |
Why?
| | Levodopa | 1 | 2017 | 29 | 0.540 |
Why?
| | Sensation Disorders | 1 | 2017 | 32 | 0.540 |
Why?
| | Tobacco Use Disorder | 1 | 2019 | 237 | 0.540 |
Why?
| | Female | 61 | 2025 | 68776 | 0.540 |
Why?
| | Humans | 80 | 2025 | 129650 | 0.530 |
Why?
| | Parkinson Disease | 3 | 2017 | 463 | 0.530 |
Why?
| | Neuropsychological Tests | 9 | 2016 | 1015 | 0.520 |
Why?
| | Sexism | 1 | 2017 | 55 | 0.510 |
Why?
| | Ventral Striatum | 1 | 2015 | 9 | 0.470 |
Why?
| | Functional Laterality | 3 | 2013 | 222 | 0.470 |
Why?
| | Ethanol | 1 | 2019 | 589 | 0.460 |
Why?
| | Attention | 4 | 2005 | 438 | 0.450 |
Why?
| | Gyrus Cinguli | 5 | 2012 | 79 | 0.420 |
Why?
| | Cognition | 2 | 2019 | 1123 | 0.420 |
Why?
| | Magnetic Resonance Angiography | 2 | 2009 | 236 | 0.410 |
Why?
| | Patient Selection | 1 | 2017 | 663 | 0.410 |
Why?
| | Cytokines | 1 | 2021 | 2017 | 0.410 |
Why?
| | Hippocampus | 7 | 2015 | 874 | 0.390 |
Why?
| | Conduct Disorder | 4 | 2017 | 199 | 0.390 |
Why?
| | Healthcare Disparities | 1 | 2017 | 578 | 0.350 |
Why?
| | Inflammation | 1 | 2021 | 2736 | 0.330 |
Why?
| | Veins | 1 | 2009 | 60 | 0.310 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 4 | 2015 | 236 | 0.310 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2008 | 17 | 0.310 |
Why?
| | Atrophy | 6 | 2024 | 171 | 0.300 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 41 | 0.300 |
Why?
| | Executive Function | 1 | 2013 | 431 | 0.290 |
Why?
| | Reaction Time | 3 | 2013 | 410 | 0.290 |
Why?
| | Middle Aged | 19 | 2024 | 31154 | 0.290 |
Why?
| | Cues | 4 | 2019 | 326 | 0.280 |
Why?
| | Analysis of Variance | 4 | 2013 | 1288 | 0.270 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2020 | 97 | 0.260 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 12 | 0.250 |
Why?
| | Dementia, Vascular | 3 | 2000 | 20 | 0.250 |
Why?
| | Pilot Projects | 2 | 2021 | 1587 | 0.240 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 1 | 2025 | 7 | 0.240 |
Why?
| | Neuroradiography | 1 | 2024 | 5 | 0.240 |
Why?
| | Evoked Potentials | 1 | 2005 | 116 | 0.230 |
Why?
| | Amyloid | 1 | 2025 | 85 | 0.220 |
Why?
| | Delay Discounting | 1 | 2023 | 18 | 0.220 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2003 | 21 | 0.220 |
Why?
| | Reference Values | 6 | 2021 | 793 | 0.210 |
Why?
| | Interview, Psychological | 2 | 2013 | 92 | 0.210 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 2002 | 2 | 0.210 |
Why?
| | Case-Control Studies | 5 | 2016 | 3381 | 0.200 |
Why?
| | Herpesvirus 1, Human | 1 | 2003 | 86 | 0.200 |
Why?
| | Thoracic Vertebrae | 1 | 2002 | 74 | 0.200 |
Why?
| | Adolescent Development | 2 | 2021 | 84 | 0.200 |
Why?
| | Marijuana Abuse | 1 | 2025 | 234 | 0.190 |
Why?
| | Administration, Oral | 2 | 2019 | 786 | 0.190 |
Why?
| | Multimodal Imaging | 2 | 2019 | 110 | 0.190 |
Why?
| | Young Adult | 7 | 2025 | 12426 | 0.190 |
Why?
| | Marijuana Use | 1 | 2025 | 192 | 0.180 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2024 | 246 | 0.180 |
Why?
| | Dementia | 1 | 2024 | 227 | 0.180 |
Why?
| | Feedback, Psychological | 2 | 2013 | 21 | 0.180 |
Why?
| | Amphetamine-Related Disorders | 2 | 2012 | 36 | 0.170 |
Why?
| | Aged | 13 | 2024 | 22103 | 0.170 |
Why?
| | Photic Stimulation | 8 | 2017 | 242 | 0.170 |
Why?
| | Immunotherapy | 1 | 2025 | 592 | 0.170 |
Why?
| | Random Allocation | 1 | 2021 | 346 | 0.170 |
Why?
| | Benzylidene Compounds | 2 | 2010 | 20 | 0.170 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1501 | 0.170 |
Why?
| | Fingers | 2 | 2013 | 86 | 0.170 |
Why?
| | Oxygen | 4 | 2017 | 915 | 0.170 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3083 | 0.170 |
Why?
| | Epilepsy | 1 | 2024 | 329 | 0.160 |
Why?
| | Cocaine-Related Disorders | 2 | 2012 | 108 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 529 | 0.160 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2019 | 14 | 0.160 |
Why?
| | Tremor | 2 | 2017 | 60 | 0.160 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7086 | 0.160 |
Why?
| | Cerebellum | 3 | 2013 | 219 | 0.160 |
Why?
| | Administration, Intravenous | 1 | 2019 | 141 | 0.150 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 1998 | 68 | 0.150 |
Why?
| | Smoking | 3 | 2012 | 1501 | 0.140 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 288 | 0.140 |
Why?
| | Selection Bias | 1 | 2017 | 37 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2013 | 521 | 0.140 |
Why?
| | Artifacts | 3 | 2009 | 126 | 0.130 |
Why?
| | Pyridines | 2 | 2010 | 478 | 0.130 |
Why?
| | Spinal Cord | 1 | 1998 | 356 | 0.130 |
Why?
| | DiGeorge Syndrome | 1 | 2016 | 29 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 2 | 2009 | 531 | 0.120 |
Why?
| | Organ Size | 3 | 2015 | 447 | 0.120 |
Why?
| | Mental Disorders | 1 | 2023 | 1030 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2024 | 1171 | 0.120 |
Why?
| | Evoked Potentials, Visual | 3 | 2002 | 35 | 0.120 |
Why?
| | Photoreceptor Cells | 2 | 1985 | 16 | 0.110 |
Why?
| | Postural Balance | 1 | 2017 | 200 | 0.110 |
Why?
| | Problem Behavior | 1 | 2015 | 92 | 0.110 |
Why?
| | Single-Blind Method | 2 | 2012 | 271 | 0.110 |
Why?
| | Brain Ischemia | 4 | 2000 | 321 | 0.110 |
Why?
| | Age Factors | 1 | 2021 | 3144 | 0.110 |
Why?
| | Nucleus Accumbens | 1 | 2015 | 126 | 0.110 |
Why?
| | Longitudinal Studies | 2 | 2021 | 2717 | 0.110 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2013 | 36 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2013 | 5406 | 0.100 |
Why?
| | Personality Inventory | 1 | 2013 | 139 | 0.100 |
Why?
| | Alcohol Drinking | 1 | 2019 | 764 | 0.100 |
Why?
| | Heroin Dependence | 1 | 2012 | 31 | 0.100 |
Why?
| | Principal Component Analysis | 1 | 2013 | 189 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2017 | 506 | 0.100 |
Why?
| | Efficiency | 1 | 2012 | 91 | 0.090 |
Why?
| | Emotions | 1 | 2017 | 538 | 0.090 |
Why?
| | Cognition Disorders | 2 | 2010 | 505 | 0.090 |
Why?
| | Adolescent | 10 | 2023 | 20393 | 0.090 |
Why?
| | Appetite Regulation | 1 | 2011 | 28 | 0.090 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.090 |
Why?
| | Fatal Outcome | 2 | 2019 | 300 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1044 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 78 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1547 | 0.090 |
Why?
| | Regression Analysis | 1 | 2013 | 993 | 0.090 |
Why?
| | Cerebrospinal Fluid | 2 | 2003 | 93 | 0.080 |
Why?
| | Inpatients | 1 | 2014 | 467 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1214 | 0.080 |
Why?
| | Sex Factors | 1 | 2015 | 1968 | 0.080 |
Why?
| | Visual Perception | 1 | 2011 | 163 | 0.080 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2008 | 9 | 0.080 |
Why?
| | Temperance | 1 | 2008 | 13 | 0.080 |
Why?
| | Nutritional Status | 1 | 2011 | 328 | 0.080 |
Why?
| | Disease Progression | 2 | 2008 | 2635 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2000 | 539 | 0.070 |
Why?
| | Energy Intake | 1 | 2011 | 461 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2024 | 2535 | 0.070 |
Why?
| | Wechsler Scales | 1 | 2007 | 53 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 329 | 0.070 |
Why?
| | Eye Movements | 2 | 2010 | 59 | 0.070 |
Why?
| | Chewing Gum | 1 | 2007 | 9 | 0.070 |
Why?
| | Alcohols | 1 | 2007 | 29 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2007 | 89 | 0.070 |
Why?
| | Alcohol-Related Disorders | 1 | 2008 | 118 | 0.070 |
Why?
| | Event-Related Potentials, P300 | 2 | 2004 | 14 | 0.070 |
Why?
| | Parietal Lobe | 2 | 2005 | 49 | 0.070 |
Why?
| | Normal Distribution | 1 | 2006 | 21 | 0.070 |
Why?
| | Electroencephalography | 3 | 2003 | 403 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1434 | 0.060 |
Why?
| | Rod Cell Outer Segment | 1 | 1985 | 3 | 0.060 |
Why?
| | Color Vision Defects | 1 | 1985 | 7 | 0.060 |
Why?
| | Dissociative Disorders | 1 | 2005 | 21 | 0.060 |
Why?
| | Models, Neurological | 1 | 2007 | 242 | 0.060 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 25 | 0.060 |
Why?
| | Taste | 1 | 2007 | 216 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 41 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2009 | 1876 | 0.060 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2025 | 23 | 0.060 |
Why?
| | Essential Tremor | 1 | 2025 | 14 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2011 | 901 | 0.060 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 126 | 0.060 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 76 | 0.050 |
Why?
| | Aspartic Acid | 3 | 2000 | 81 | 0.050 |
Why?
| | Child | 5 | 2024 | 20883 | 0.050 |
Why?
| | Connectome | 1 | 2025 | 84 | 0.050 |
Why?
| | Ocular Motility Disorders | 1 | 2004 | 26 | 0.050 |
Why?
| | Personnel Selection | 1 | 2024 | 72 | 0.050 |
Why?
| | Aphasia | 1 | 2003 | 21 | 0.050 |
Why?
| | Psychopathology | 1 | 2023 | 50 | 0.050 |
Why?
| | United States | 3 | 2025 | 13903 | 0.050 |
Why?
| | Brain Diseases | 1 | 2024 | 137 | 0.050 |
Why?
| | Temporal Lobe | 1 | 2003 | 87 | 0.050 |
Why?
| | Pattern Recognition, Visual | 1 | 2004 | 98 | 0.050 |
Why?
| | Echo-Planar Imaging | 1 | 2002 | 18 | 0.050 |
Why?
| | Heart Rate | 1 | 2007 | 802 | 0.050 |
Why?
| | Acetazolamide | 1 | 2022 | 24 | 0.050 |
Why?
| | Mental Processes | 1 | 2002 | 38 | 0.050 |
Why?
| | Radiology | 1 | 2024 | 161 | 0.050 |
Why?
| | Fourier Analysis | 1 | 2002 | 39 | 0.050 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2005 | 45 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2014 | 10230 | 0.050 |
Why?
| | Decompression, Surgical | 1 | 2002 | 99 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2024 | 481 | 0.050 |
Why?
| | Motor Activity | 1 | 2006 | 676 | 0.050 |
Why?
| | Stroke | 2 | 2019 | 1071 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2024 | 264 | 0.050 |
Why?
| | Language | 1 | 2024 | 283 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2004 | 263 | 0.040 |
Why?
| | Incidental Findings | 1 | 2021 | 79 | 0.040 |
Why?
| | Liver Diseases | 1 | 2003 | 290 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 1038 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 751 | 0.040 |
Why?
| | Seizures | 1 | 2003 | 402 | 0.040 |
Why?
| | Blood Pressure | 1 | 2007 | 1736 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1838 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 2005 | 436 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 759 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1622 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2019 | 19 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2019 | 35 | 0.040 |
Why?
| | Cerebral Infarction | 1 | 1999 | 42 | 0.040 |
Why?
| | Coloring Agents | 1 | 2019 | 77 | 0.040 |
Why?
| | Optical Imaging | 1 | 2019 | 56 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2019 | 144 | 0.040 |
Why?
| | Obesity | 1 | 2011 | 2883 | 0.040 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 547 | 0.040 |
Why?
| | Brain Chemistry | 1 | 1998 | 118 | 0.040 |
Why?
| | Cannabis | 1 | 2025 | 465 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 187 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 404 | 0.040 |
Why?
| | Animals | 2 | 2019 | 35361 | 0.030 |
Why?
| | Visual Acuity | 1 | 2019 | 322 | 0.030 |
Why?
| | Cerebral Ventricles | 1 | 1997 | 50 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 758 | 0.030 |
Why?
| | Motor Neurons | 1 | 1998 | 236 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 732 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2012 | 0.030 |
Why?
| | Empathy | 1 | 2017 | 170 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 44 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 496 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6556 | 0.030 |
Why?
| | Glucose | 1 | 1999 | 1003 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5066 | 0.030 |
Why?
| | Hyperphagia | 1 | 2011 | 34 | 0.020 |
Why?
| | Sensation | 1 | 2011 | 51 | 0.020 |
Why?
| | Labor, Induced | 1 | 2011 | 30 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5420 | 0.020 |
Why?
| | Thinness | 1 | 2011 | 89 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 87 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2011 | 232 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7133 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 164 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 130 | 0.020 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 1 | 2010 | 104 | 0.020 |
Why?
| | Food | 1 | 2011 | 157 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 267 | 0.020 |
Why?
| | Creatine | 2 | 2000 | 58 | 0.020 |
Why?
| | Hemodynamics | 1 | 2013 | 1090 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1040 | 0.020 |
Why?
| | Aspirin | 1 | 2011 | 380 | 0.020 |
Why?
| | Dominance, Cerebral | 1 | 2007 | 54 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 522 | 0.020 |
Why?
| | Nerve Fibers | 1 | 2007 | 89 | 0.020 |
Why?
| | Weight Loss | 1 | 2011 | 734 | 0.020 |
Why?
| | Cranial Nerves | 1 | 2005 | 12 | 0.020 |
Why?
| | Sural Nerve | 1 | 2005 | 18 | 0.020 |
Why?
| | Genotype | 1 | 2010 | 1839 | 0.010 |
Why?
| | Graves Disease | 1 | 2005 | 35 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 121 | 0.010 |
Why?
| | Visual Pathways | 1 | 2005 | 50 | 0.010 |
Why?
| | Schizophrenic Psychology | 1 | 2005 | 94 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 304 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 340 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2005 | 299 | 0.010 |
Why?
| | Genetic Markers | 1 | 2005 | 338 | 0.010 |
Why?
| | Visual Fields | 1 | 2004 | 87 | 0.010 |
Why?
| | Early Diagnosis | 1 | 2005 | 234 | 0.010 |
Why?
| | Axons | 1 | 2005 | 191 | 0.010 |
Why?
| | Myelin Sheath | 1 | 2005 | 160 | 0.010 |
Why?
| | Gene Frequency | 1 | 2005 | 503 | 0.010 |
Why?
| | Phenytoin | 1 | 1983 | 20 | 0.010 |
Why?
| | Head | 1 | 2004 | 96 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2004 | 159 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2073 | 0.010 |
Why?
| | Electrolytes | 1 | 1983 | 60 | 0.010 |
Why?
| | Visual Cortex | 1 | 2002 | 68 | 0.010 |
Why?
| | Movement | 1 | 2004 | 269 | 0.010 |
Why?
| | Risk | 1 | 2004 | 854 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 853 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1999 | 66 | 0.010 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 77 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6402 | 0.010 |
Why?
| | Protons | 1 | 1997 | 80 | 0.010 |
Why?
| | Choline | 1 | 1998 | 124 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2004 | 2282 | 0.010 |
Why?
| | Biomarkers | 1 | 2005 | 3973 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2742 | 0.010 |
Why?
| | Dogs | 1 | 1983 | 381 | 0.000 |
Why?
|
|
Tanabe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|